Sofie signs deal with ABX for cGMP compliance

By staff writers

October 10, 2019 -- Molecular imaging developer Sofie Biosciences has signed an agreement with ABX Advanced Biochemical Compounds of Radeberg, Germany, for ABX to provide Sofie with current good manufacturing practice (cGMP) precursor and reference standards for Sophie's fibroblast activation protein inhibitor (FAPI) compounds.

Sofie said the deal will support its ongoing clinical development of these compounds.

Copyright © 2019

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking